Quantcast

Latest Nelfinavir Stories

2012-10-08 13:27:11

The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV, according to a study published October 5 in the Journal of the National Cancer Institute. Breast cancer is one of the most common causes of cancer deaths in the U.S. with approximately 39,520 women succumbing to the disease in 2011. HER2-postive breast cancer is known to be more aggressive and less responsive to treatments compared...

2012-06-22 06:15:16

(Ivanhoe Newswire) -- About 0.2% of pregnant women are HIV positive and 1/3 will pass the virus to their baby before it is born if no treatment is given. A new study breaches the safety and efficacy of adding antiretroviral drugs (HIV treatment drugs) to standard zidovudine prophylaxis (standard HIV prevention drugs) in infants of mothers with HIV who did not receive antenatal antiretroviral therapy because of late identification. Within 48 hours after their birth, researchers randomly...

2011-04-29 14:02:11

Use of chemical systems biology may represent the future of drug discovery Researchers at the University of California, San Diego and Hunter College of the City University of New York (CUNY) have identified potential human molecular targets of the anti-HIV drug Nelfinavir, which may explain why the drug is also effective as a cancer therapy. Their study will be published in the online edition of PLoS Computational Biology on April 28. Nelfinivir is a protease inhibitor that prevents...

2011-04-29 13:34:53

Potential molecular targets of the anti-HIV drug nelfinavir have been identified, and may explain why the drug is also effective as a cancer therapy. Findings will be published in the open-access journal PLoS Computational Biology on 28th April 2011. Nelfinavir is a protease inhibitor that prevents replication of the HIV virus. It has also been found to have a positive effect on a number of solid tumor types but the mechanism of how the drug worked in humans was unclear. Researchers from the...

2011-04-11 07:00:00

DENVER, April 11, 2011 /PRNewswire/ -- MusclePharm Corporation, a Nevada corporation ("MusclePharm" or the "Company") (OTCBB: MSLP), an expanding U.S. nutritional supplement company, is pleased to announce the addition of Richard Ogden, PhD, to its medical advisory board. "It is a great honor to welcome Dr. Ogden to the MusclePharm team," stated Cory Gregory, President of MusclePharm. "Dr. Ogden's extensive knowledge and experience in launching HIV medications for global pharmaceutical...

2010-07-19 05:30:00

VIENNA, July 19 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients....

2010-04-28 10:47:00

ABBOTT PARK, Ill., April 28 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) approved once-daily dosing of Kaletra® (lopinavir/ritonavir) for adult patients with HIV who have previously taken antiretroviral therapy. Kaletra once-daily dosing is already indicated for adult patients new to antiretroviral treatment. This gives treatment-experienced patients who have HIV that responds to Kaletra another dosing option as determined by...

2009-03-03 10:58:19

New findings may significantly improve the safety of methadone, a drug widely used to treat cancer pain and addiction to heroin and other opioid drugs, according to researchers at Washington University School of Medicine in St. Louis and the University of Washington in Seattle. The researchers discovered that the body processes methadone differently than previously believed. Those incorrect assumptions about methadone have been making it difficult for physicians to understand how and when the...

2008-08-07 18:01:53

MEXICO CITY, Aug. 7 /PRNewswire-FirstCall/ -- Abbott presented pivotal data at the XVII International AIDS Conference (AIDS 2008) in Mexico City today showing that its investigational Norvir(R) (ritonavir) tablet and the current soft-gelatin capsule provide similar levels of drug in the blood. The heat-stable Norvir tablet will not require refrigeration, making it more convenient for patients to use, particularly in developing countries where the majority of people with HIV live. "The...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.